Skip to main content
Erschienen in: Internal and Emergency Medicine 2/2024

17.01.2024 | IM - ORIGINAL

Renal function modifies the association between hemoconcentration and outcomes in hospitalized heart failure patients

verfasst von: Liyan Huang, Xuemei Zhao, Lin Liang, Pengchao Tian, Yuyi Chen, Mei Zhai, Yan Huang, Qiong Zhou, Yuhui Zhang, Jian Zhang

Erschienen in: Internal and Emergency Medicine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Evidence-based management of decongestion is lacking in hospitalized heart failure (HHF) patients, especially in patients with impaired renal function. Hemoconcentration is an objective measure of decongestion that portends a favorable prognosis and guides management in HHF patients with preserved renal function. We aim to investigate whether it remains a prognosticator in patients with renal impairment, and to refine the identification of subpopulations who will benefit from hemoconcentration-guided therapy. HHF patients admitted to Heart Failure Center of Fuwai Hospital were consecutively included from December 2006 to June 2018. Patient characteristics were depicted. Relationships between in-hospital hemoconcentration, worsening renal function (WRF), and one-year all-cause mortality were investigated in the total population and compared between renal function groups using survival analysis and cubic splines, with a special focus on renal function-based interactions. The association was further validated in sensitivity analyses. Clinically relevant cut-offs and subpopulations were identified by subpopulation treatment effect pattern plots (STEPP) and subgroup analysis. 3661 participants (30.4% with impaired renal function) were included. Hemoconcentration, reflected by an in-hospital increase in hemoglobin, hematocrit, or a relative reduction in estimated plasma volume from baseline to discharge, was predictive of decreased one-year mortality in the total cohort despite its correlation with higher WRF incidence. The prognostic value of hemoconcentration differed in patients with impaired and preserved renal function. Hemoconcentration was related to a favorable prognosis in patients with preserved renal function (HR, 0.69; 95% CI, 0.53–0.90; P = 0.007), especially in young male patients with New York Heart Association functional class III–IV, reduced ejection fraction, and baseline eGFR > 75 mL/min/1.73m2. Contrarily, impaired renal function patients experienced a higher incidence of WRF, and hemoconcentration was no longer related to outcome (HR, 0.90; 95% CI, 0.64–1.26; P = 0.545), with findings consistent in all clinically relevant subgroups. In HHF patients, the prognostic value of hemoconcentration differs by renal function, and the clinical utility of hemoconcentration is contingent on preserved renal function.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G (2013) Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 15(12):1401–1411. https://doi.org/10.1093/eurjhf/hft110CrossRefPubMedPubMedCentral Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G (2013) Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 15(12):1401–1411. https://​doi.​org/​10.​1093/​eurjhf/​hft110CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat van der Meer P, Postmus D, Ponikowski P, Cleland JG, O’Connor CM, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA (2013) The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 61(19):1973–1981. https://doi.org/10.1016/j.jacc.2012.12.050CrossRefPubMed van der Meer P, Postmus D, Ponikowski P, Cleland JG, O’Connor CM, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA (2013) The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 61(19):1973–1981. https://​doi.​org/​10.​1016/​j.​jacc.​2012.​12.​050CrossRefPubMed
10.
Zurück zum Zitat Ferreira JP, Girerd N, Pellicori P, Duarte K, Girerd S, Pfeffer MA, McMurray JJ, Pitt B, Dickstein K, Jacobs L, Staessen JA, Butler J, Latini R, Masson S, Mebazaa A, Rocca HP, Delles C, Heymans S, Sattar N, Jukema JW, Cleland JG, Zannad F, Rossignol P (2016) Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart “OMics” in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Med 14(1):181. https://doi.org/10.1186/s12916-016-0731-2CrossRefPubMedPubMedCentral Ferreira JP, Girerd N, Pellicori P, Duarte K, Girerd S, Pfeffer MA, McMurray JJ, Pitt B, Dickstein K, Jacobs L, Staessen JA, Butler J, Latini R, Masson S, Mebazaa A, Rocca HP, Delles C, Heymans S, Sattar N, Jukema JW, Cleland JG, Zannad F, Rossignol P (2016) Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart “OMics” in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Med 14(1):181. https://​doi.​org/​10.​1186/​s12916-016-0731-2CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Blumer V, Greene SJ, Sun JL, Bart BA, Ambrosy AP, Butler J, DeVore AD, Fudim M, Hernandez AF, McNulty SE, Felker GM, Mentz RJ (2019) Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. Eur J Heart Fail 21(11):1472–1476. https://doi.org/10.1002/ejhf.1592CrossRefPubMed Blumer V, Greene SJ, Sun JL, Bart BA, Ambrosy AP, Butler J, DeVore AD, Fudim M, Hernandez AF, McNulty SE, Felker GM, Mentz RJ (2019) Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. Eur J Heart Fail 21(11):1472–1476. https://​doi.​org/​10.​1002/​ejhf.​1592CrossRefPubMed
15.
Zurück zum Zitat Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ, Palazzuoli A, Barragan PM, Thum T, Marcos MC, Miró Ò, Rossignol P, Metra M, Lassus J, Orso F, Jankowska EA, Chioncel O, Milicic D, Hill L, Seferovic P, Rosano G, Coats A, Damman K (2022) Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 24(4):603–619. https://doi.org/10.1002/ejhf.2471CrossRefPubMed Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ, Palazzuoli A, Barragan PM, Thum T, Marcos MC, Miró Ò, Rossignol P, Metra M, Lassus J, Orso F, Jankowska EA, Chioncel O, Milicic D, Hill L, Seferovic P, Rosano G, Coats A, Damman K (2022) Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 24(4):603–619. https://​doi.​org/​10.​1002/​ejhf.​2471CrossRefPubMed
16.
Zurück zum Zitat Voors AA, Damman K, Teerlink JR, Angermann CE, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P (2022) Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail 24(10):1844–1852. https://doi.org/10.1002/ejhf.2681CrossRefPubMed Voors AA, Damman K, Teerlink JR, Angermann CE, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P (2022) Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail 24(10):1844–1852. https://​doi.​org/​10.​1002/​ejhf.​2681CrossRefPubMed
19.
Zurück zum Zitat Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A (2020) Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22(4):584–603. https://doi.org/10.1002/ejhf.1697CrossRefPubMed Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, Tang WHW, Skouri H, Verbrugge FH, Orso F, Hill L, Ural D, Lainscak M, Rossignol P, Metra M, Mebazaa A, Seferovic P, Ruschitzka F, Coats A (2020) Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22(4):584–603. https://​doi.​org/​10.​1002/​ejhf.​1697CrossRefPubMed
20.
Zurück zum Zitat Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, Cleland JGF, Davison BA, Felker GM, Givertz MM, Greenberg B, Pang PS, Severin T, Gimpelewicz C, Metra M, Voors AA, Teerlink JR (2022) Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail 24(2):365–374. https://doi.org/10.1002/ejhf.2384CrossRefPubMed Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, Cleland JGF, Davison BA, Felker GM, Givertz MM, Greenberg B, Pang PS, Severin T, Gimpelewicz C, Metra M, Voors AA, Teerlink JR (2022) Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail 24(2):365–374. https://​doi.​org/​10.​1002/​ejhf.​2384CrossRefPubMed
21.
Zurück zum Zitat Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, Adamopoulos S, Anker SD, Antohi L, Böhm M, Braunschweig F, Gal TB, Butler J, Cleland JGF, Cohen-Solal A, Damman K, Gustafsson F, Hill L, Jankowska EA, Lainscak M, Lund LH, McDonagh T, Mebazaa A, Moura B, Mullens W, Piepoli M, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Sharma R, Tocchetti CG, Yilmaz MB, Vitale C, Volterrani M, von Haehling S, Chioncel O, Coats AJS, Rosano G (2023) Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the heart failure association of the European society of cardiology. Eur J Heart Fail 25(6):776–791. https://doi.org/10.1002/ejhf.2874CrossRefPubMed Metra M, Tomasoni D, Adamo M, Bayes-Genis A, Filippatos G, Abdelhamid M, Adamopoulos S, Anker SD, Antohi L, Böhm M, Braunschweig F, Gal TB, Butler J, Cleland JGF, Cohen-Solal A, Damman K, Gustafsson F, Hill L, Jankowska EA, Lainscak M, Lund LH, McDonagh T, Mebazaa A, Moura B, Mullens W, Piepoli M, Ponikowski P, Rakisheva A, Ristic A, Savarese G, Seferovic P, Sharma R, Tocchetti CG, Yilmaz MB, Vitale C, Volterrani M, von Haehling S, Chioncel O, Coats AJS, Rosano G (2023) Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the heart failure association of the European society of cardiology. Eur J Heart Fail 25(6):776–791. https://​doi.​org/​10.​1002/​ejhf.​2874CrossRefPubMed
22.
Zurück zum Zitat Lorenzo M, Núñez G, Fuertes-Kenneally L, de la Espriella R, Villar S, Miró O, Llorens P, Santas E, Miñana G, Bodí V, Sanchis J, Carratalá A, Bayés-Genís A, Núñez J (2023) Early glomerular filtration rates changes and risk of mortality in acute heart failure. The modifying role of admission renal function and decongestion. Eur J Intern Med 115:96–103. https://doi.org/10.1016/j.ejim.2023.05.037CrossRefPubMed Lorenzo M, Núñez G, Fuertes-Kenneally L, de la Espriella R, Villar S, Miró O, Llorens P, Santas E, Miñana G, Bodí V, Sanchis J, Carratalá A, Bayés-Genís A, Núñez J (2023) Early glomerular filtration rates changes and risk of mortality in acute heart failure. The modifying role of admission renal function and decongestion. Eur J Intern Med 115:96–103. https://​doi.​org/​10.​1016/​j.​ejim.​2023.​05.​037CrossRefPubMed
23.
Zurück zum Zitat Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61(2):196–206. https://doi.org/10.1016/j.jacc.2012.11.005CrossRefPubMed Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61(2):196–206. https://​doi.​org/​10.​1016/​j.​jacc.​2012.​11.​005CrossRefPubMed
25.
Zurück zum Zitat Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80(6):572–586. https://doi.org/10.1038/ki.2011.223CrossRefPubMed Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80(6):572–586. https://​doi.​org/​10.​1038/​ki.​2011.​223CrossRefPubMed
Metadaten
Titel
Renal function modifies the association between hemoconcentration and outcomes in hospitalized heart failure patients
verfasst von
Liyan Huang
Xuemei Zhao
Lin Liang
Pengchao Tian
Yuyi Chen
Mei Zhai
Yan Huang
Qiong Zhou
Yuhui Zhang
Jian Zhang
Publikationsdatum
17.01.2024
Verlag
Springer International Publishing
Erschienen in
Internal and Emergency Medicine / Ausgabe 2/2024
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-023-03488-1

Weitere Artikel der Ausgabe 2/2024

Internal and Emergency Medicine 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

CKD bei Diabetes: Neuheiten und Zukunftsaussichten

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.